News
HIV diagnosis at home and same-day ART start tied to better outcomes
Home HIV diagnosis coupled to same-day ART initiation may help rural patients.
News
One-month TB-prevention regimen effective in HIV+ individuals
New, shorter TB regimen is effective and could up adherence in HIV-positive individuals.
News
Avelumab safety compares with other checkpoint inhibitors
Although about two-thirds of patients had treatment-related adverse events, most experienced only mild or moderate ones.
News
Prostate cancer survival similar with EBRT/brachytherapy or surgery, analysts claim
An analysis of cancer registry data suggests that surgery and external beam radiotherapy plus brachytherapy have similar survival outcomes in...
News
Export protein inhibitor shows activity against refractory myeloma
The combination of selinexor with dexamethasone looks most promising for this hard-to-treat population.
News
Mycosis fungoides increases risk for second cancers
LA JOLLA, CALIF. – The study mines data from the SEER-18 database.
News
Basiliximab/BEAM may improve post-ASCT outcomes in PTCL
LA JOLLA, CALIF. – The phase 1 trial is testing the use of a CD25 monoclonal antibody for achieving long-term remission in PTCL.
News
Axitinib/pembrolizumab combo safe, effective against mRCC
At a median of 20.4 months of follow-up, the overall response rate was 73% in an open-label phase 1b dose-finding trial and expansion in 52...
News
Denosumab on par with zoledronic acid for multiple myeloma bone disease
The results come from a phase 3 randomized trial of patients with newly diagnosed multiple myeloma with one or more lytic bone lesions.
News
A view from the bridge to transplant for PTCL
LA JOLLA, CALIF. – Subtype and timing matter when considering the best bridge to transplant.
News
Getting hematologic cancer drugs on the fast track
In 2017, the FDA approved 17 agents for new or expanded indications for hematologic malignancies, including one agent for anaplastic large cell...
News
T-cell lymphoma therapies on the horizon
LA JOLLA, CALIF. – Three new agents are in the pipeline for T-cell lymphoma.
News
VIP an unwelcome contributor to eosinophilic esophagitis
Experimental inhibition of the vasoactive intestinal peptide–CRTH2 axis could reduce the hallmark symptoms of EoE.
News
Desmoplastic melanoma yields to checkpoint inhibitors
Of 60 patients with desmoplastic melanoma treated with checkpoint inhibitors and followed for a median of 22 months, 42 had an objective response...
News
VcR-CVAD yields high responses, ‘excellent’ survival in MCL
The moderate-intensity induction and maintenance regimen induced good responses in both younger and older patients.